5 Simple Techniques For Antidepressant agent 5
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze To guage several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Key demo objectives have been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis